On March 7, 2022, the Board of Directors  of Rocket Pharmaceuticals, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Fady Malik, M.D., Ph.D., to the Board, effective March 10, 2022. Dr. Malik will hold office until the earlier of the Company's annual meeting of stockholders in 2022 or until his successor is elected and duly qualified, or until his death, resignation or removal. Dr. Malik will serve as a member of the Board as of March 10, 2022.

Dr. Malik has served as the Executive Vice President of Research and Development at Cytokinetics, Inc. since November 2015, and he has been with Cytokinetics since its inception in 1998. Prior to taking on his current role in 2015, Dr. Malik had several other roles of increasing seniority within Cytokinetics, including serving as the Senior Vice President of Research and Development from August 2014 to November 2015. On March 10, 2022, John Militello, the Company's Vice President – Finance, Senior Controller, Treasurer and Principal Accounting Officer, was appointed as the interim Principal Financial Officer of the Company, as of the effective date of Mr. Garcia-Parada's resignation.

On March 10, 2022, Carlos Garcia-Paradatendered his resignation as Principal Financial Officer of the Company, effective March 16, 2022, due to personal reasons. Mr. Garcia-Paradawill continue to serve as an advisor to the Company until March 31, 2022.